Study of Trilaciclib and Lurbinectidin (NCT05578326)
Study of Trilaciclib and Lurbinectedin in Small Cell Lung Cancer
🩺 Plain-English Summary (8th-Grade Level)
Lung cancer is by far the leading cause of cancer death among both men and women worldwide and the second most common cancer in terms of new cases. Small cell lung cancer (SCLC) is the deadliest form of lung cancer. The standard first-line treatment is the combination of carboplatin, etoposide, and atezolizumab. While response rates for this regimen are high (roughly 60%), the duration of response is short, typically 4 months. Following progression after the 1st line treatment of SCLC, there is no consensus regarding subsequent therapy. Lurbinectedin is FDA approved and is increasingly preferred in clinical practice. Toxicity was significant, but appeared favorable compared to historic results with topotecan, leading to the adoption of this therapy for second-line SCLC. The toxicity profile was dominated by myelosuppression. This study investigates the effect of Trilaciclib on myelosuppression rate in subjects with platinum refractory extensive stage (ES)- SCLC receiving Lurbinectedin as well as the clinical synergy of Trilaciclib and Lurbinectedin combination.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (6 items).
Location: Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Active infection requiring systemic therapy.
- Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
- Treatment with any investigational drug within 4 weeks prior to start of treatment.
- A known allergy or sensitivity to either study drug or its excipients.
- Subject is receiving prohibited medications or treatments as listed in the protocol.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (2 Sites)
- Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire
- Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill — Chapel Hill, North Carolina
📞 Contact the Study Coordinator
Phone: (919) 966-4432
Email: shamina_williams@med.unc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lung Cancer
- Precision Lung Cancer Survivorship Care Intervention — Lexington, Kentucky
- Implementation Strategies for Monitoring Adherence in Real Time — Philadelphia, Pennsylvania
- Deep Learning Using Chest X-Rays to Identify High Risk Patients for Lung Cancer Screening CT — Boston, Massachusetts
- Study Comparing Two Different Schedules of Radiation for Early-stage Lung Cancer — Rochester, New York
- Early Detection of Lung Cancer — Nashville, Tennessee
Explore by condition: All Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.